^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:zotatifin (eFT226) (eIF4A1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

    Excerpt:
    ...- Tumor has a known KRAS-activating mutation; Patients with KRAS G12C mutations are excluded....
    Trial ID:
    NCT04092673
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 1955: Inhibition of eIF4A by eFT226 blocks KRAS mutant tumor growth

    Published date:
    05/15/2020
    Excerpt:
    In a cell panel screen for in vitro apoptosis induction by eFT226, the most sensitive models were enriched for cell lines driven by KRAS mutations. Consistent with these results, treatment with eFT226 decreased KRAS protein levels, repressed downstream MAPK signaling, inhibited cell proliferation, and induced apoptosis in a collection of non-small cell lung, colorectal and pancreatic KRAS mutant cancer cell lines...Together, these results highlight the ability of eFT226 to inhibit growth and promote apoptosis in KRAS mutant tumors and support the clinical development of eFT226 in KRAS driven tumors.
    DOI:
    10.1158/1538-7445.AM2020-1955